OVER THE PAST DECADE, clinical pharmacists have served as teachers, researchers, and practitioners. The key question is, "Is there a specific role a clinical pharmacist must play?" A general answer to this question can be found in the common thread of the various definitions of the clinical pharmacist, namely, that this individual should improve the quality of patient care. This answer is simple, but complex issues often are raised about the way it should be carried out in practice. We often hear it said that a clinical pharmacist should provide clinical service; teach pharmacy students, fellow pharmacists, nurses, and physicians; and do research. The challenge is to establish priorities among these activities, particularly in training clinical pharmacists.
Individual clinical pharmacists' roles will vary from situation to situation. Four factors should be considered for a proper perspective on the various alternatives and opportunities for optimal contribution to patient care.
Qualifications and Interests of the Clinical Pharmacist. Pharm.D. programs differ in curriculum content and faculty expertise, leading to diversity in the education and practical training of clinical pharmacists. Furthermore, Pharm.D. students in the same program may have varying interests; some of these students may complete residencies or research fellowships that produce greater subspecialty skills. Additional experience in specific areas of practice, teaching, and research, along with a personal interest in further growth and development in a given area, should help determine the activities of a clinical pharmacist. It should be noted that most clinical pharmacists will excell only in one or two of the three areas of practice, teaching, and research.
Needs of the Employer. Needs of the Clinical Site. This factor often is not considered with proper emphasis. The needs of a community hospital may be different from those in a university hospital. In addition, even within a hospital, the needs for clinical pharmacy services may vary substantially from one subspecialty to another. For example, consults about antibiotic therapy frequently are sought from clinical pharmacists in a community hospital with no full-time, infectious-disease physician specialist, or in a surgical intensive care unit with severely ill patients with multiple organ failure, who are generally supervised by an anesthesiologist/surgeon. The clinical pharmacist's advice may not be needed as frequently in an infectious-disease unit that has several physician specialists. In the latter situation, the need for collaborative research may be greater than the need for clinical practice. In such cases, would it be wise to spend a large portion of the day attending patient rounds and providing a drug information service? analytical equipment, space) and patient population are limited.
If these four factors are considered properly, clinical pharmacists may be able to contribute maximally to patient care and to achieve the professional respect of peers, physicians, nurses, and other members of the health care team. Whatever the decision about the relative emphases among teaching, practice, and research, the clinical pharmacist must strive to achieve the highest potential in each area. High quality in one or two areas may be far more important than shallow activities in all three.
We should be open minded and flexible in our thinking and should look for the areas of unique contribu-
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Effect of Amikacin and Gentamicin on Urinary Enzyme Excretion
TO THE EDITOR: Previous experimental investigations have demonstrated that enzymuria is an early sign of aminoglycoside nephrotoxicity.' Because the animal model does not mimic the human model accurately,' and since most of the work on enzyme excretion after aminoglycoside therapy has been performed on animals or healthy humans, we studied the urinary -y-glutamyl transferase (GGT) and leucin aminopeptidase (LAP) activities in two groups, one consisting of six patients and the other of seven patients, with gram-negative infections treated with gentamicin and amikacin, respectively. Furthermore, we compared the enzymuria levels with urinary volume and creatinine clearance (Cl er ) to gain more knowledge of aminoglycoside effects on the human kidney.
Thirteen patients with a diagnosis of urinary gram-negative infections were enrolled in this study after they or their families had given informed consent. Six patients (four females, two males) with a mean age of 64 years (range, 46-79) received gentamicin for nine days at the usual dosage of 80 mg im q8h; seven other patients (five females, two males) with a mean age of 63 years (range, 13-87) received amikacin 500 mg ql2h for nine days. Baseline 24-hour urine volume, Cl cro GGT, and LAP were obtained the day before aminoglycoside treatment was begun and daily until the completion of the nine-day treatment period. A further group of five patients with diverse infection (four males, I female) witha mean age of 52 years (range, 34-64), treated for the same period with ampicillin I g im q6h for nine days, served as a control group. Urinary GGT and LAP activities were assayed by a spectrophotometric method at 30°C according to Szasz ' and Nagel." Cl cr was measured in a Beckman autoanalyzer using the method of Jaffe.' Statistical significance was evaluated by Student's r-test for unpaired or paired values as convenient; p values <0.05 were considered significant. The results are expressed as mean ± SEM. Figure I shows the basal levels of urine GGT and LAP activities on the different treatment days. The absolute values at all times have been converted into percentages, with basal values representing 100 tion. We can play many roles to satisfy the existing and changing needs. It may not be wise, however, to be complacent because we go on rounds or conduct clinical studies. It may be proper for a practitioner to ask, "What unique contribution did the pharmacist make during rounds?" or "Which questions could have been answered easily by others?" or, most important, "What would happen without the presence of a clinical pharmacist during rounds?" Researchers also must continually assess the uniqueness of their contributions and the impact of such contributions on improving drug therapy. This type of introspection may provide an enriched environment of mutual respect, which is so important for the advancement of our profession. percent. For amikacin treatment, differences were statistically significant for GGT on days 4,5,6,7,8, and 9 and for LAP on days 2, 3,4,5,6,7,8, and 9 . For gentamicin treatment, the differences were significant for GGT on days 3,5,6, and 9 and for LAP on days 3,4,5,6,8, and 9.
Neither urine volume nor Cl cr suffered any significant modification during the nine days of gentamicin or amikacin therapy. Urinary GGT and LAP, Cl.,; and urine output remained unchanged throughout the study in the ampicillin group.
Aminoglycosides are important in the clinical management of gramnegative infections. Gentamicin and amikacin are used extensively for that purpose, but both are nephrotoxic. In a clinical trial, Smith et al. have shown therapeutic effectiveness and nephrotoxicity in humans to be similar with administration of gentamicin and arnikacin." This complication was identified using a standard renal function test. Although the nephrotoxicity index induced by aminoglycosides in the general population is low (3-11 percent for gentamicin' and 8.7 percent for arnikacin"), it is manifested as an acute tubular necrosis (1-2 percent) and/or decreases in Cl., (10-20 percent), or as a gradual rise in serum creatinine without acute tubular necrosis; which is sometimes reversible when the drug is discontinued. '0 It is difficult to compare aminoglycoside nephrotoxicity among different aminoglycosides due to the lack of uniformity in the methods used by authors to diagnose renal toxicity. Some studies indicate that amikacin accumulates in renal tissues to a greater extent than gentamicin and is, therefore, more nephrotoxic." 
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